Search the web
Welcome, Guest
[Sign Out, My Account]
 EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI 		Symbol Lookup | Financial Search
EPCT > SEC Filings for EPCT > Form 8-K on 21-Feb-2013All Recent SEC Filings

Show all filings for EPICEPT CORP | Request a Trial to NEW EDGAR Online Pro

Form 8-K for EPICEPT CORP

21-Feb-2013

Other Events, Financial Statements and Exhibits


Item 8.01 Other Events.

On February 21, 2013, EpiCept Corporation and its proposed merger partner, Immune Pharmaceuticals Ltd. ("Immune") announced that Immune is initiating, following authorization from Israeli health authorities, a Phase II double-blind placebo controlled study with its lead drug, bertilimumab, in patients with moderate-to-severe ulcerative colitis. Bertilimumab is a first-in-class fully human monoclonal antibody targeting eotaxin-1, a chemokine small protein regulating eosinophilic inflammation. The press release is attached hereto as Exhibit 99.1.



Item 9.01 Financial Statements and Exhibits.

99.1 Press release dated February 21, 2013.

Top of the Form

  Add EPCT to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for EPCT - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now

Copyright © 2013 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.